Idorsia takes steps to address short-term liquidity needs
April 11, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR A bondholders meeting is expected to take place on April 30, 2024, to request the right to repay the bonds maturing in 2024, fully or partially in shares...
Idorsia takes steps to address short-term liquidity needs
April 11, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR A bondholders meeting is expected to take place on April 30, 2024, to request the right to repay the bonds maturing in 2024, fully or partially in shares...
Idorsia thanks Guy Braunstein for his years of service as he retires
March 22, 2024 02:00 ET
|
Idorsia Pharmaceuticals Ltd
Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024 Allschwil, Switzerland – March 22, 2024Idorsia Ltd (SIX: IDIA) today...
Idorsia thanks Guy Braunstein for his years of service as he retires
March 22, 2024 02:00 ET
|
Idorsia Pharmaceuticals Ltd
Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024 Allschwil, Switzerland – March 22, 2024Idorsia Ltd (SIX: IDIA) today...
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
March 20, 2024 02:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult...
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
March 20, 2024 02:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult...
Idorsia and Viatris successfully close the transaction for the global research and development collaboration
March 18, 2024 02:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 18, 2024Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ:...
Idorsia and Viatris successfully close the transaction for the global research and development collaboration
March 18, 2024 02:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 18, 2024Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ:...
Idorsia and Viatris enter into a significant global research and development collaboration
February 28, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an...
Idorsia and Viatris enter into a significant global research and development collaboration
February 28, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an...